Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label, multicenter, multi cohort, study of VS-6063 (defactinib), a
focal adhesion kinase inhibitor, in patients with KRAS mutant non-small cell lung cancer
(NSCLC). NSCLC with a KRAS mutation is required for study entry and subjects will be enrolled
into 1 of 4 cohorts based on the status of their INK4a/Arf and p53 mutations. The purpose of
this study is to demonstrate if VS-6063 (defactinib) improves PFS within each cohort. The
safety and tolerability of VS-6063, tumor response rate, progression free survival and
overall survival will also be assessed. The pharmacodynamic effects of VS-6063 (defactinib)
will be examined in a tumor biopsy and a blood sample.